The HemOnc Pulse Live at ASH: Phillip Scheinberg, MD, on CHIP, MDS Classification Updates
By Chadi Nabhan, MD, MBA, FACP, Phillip Scheinberg, MD - Last Updated: January 10, 2023Phillip Scheinberg, MD, talks about developments in research and treatment for myelodysplastic syndromes (MDS) with Chadi Nabhan, MD, MBA, FACP, host of The HemOnc Pulse, during the 2022 American Society of Hematology Annual Meeting. Dr. Scheinberg and Dr. Nabhan discussed MDS classification updates, clonal hematopoiesis of indeterminate potential, the evolution of MDS, and more.
Advertisement
Post Tags:MDS ASH 22
Advertisement
Related Posts
New data on immune thrombocytopenia were most prominent but Meeting coverage ranged over several forms of the disease.
Andrew Kuykendall, MD, presented on the status of myelofibrosis treatment in the era of 4 approved JAK inhibitors.
The CARTITUDE-4, KarMMa-3, and DREAMM-7 trials are paving the way for immunotherapy in multiple myeloma.
A panel moderated by Neil Love, MD, explored clinical data to assess these treatment approaches for the various types of NHL.
The several considerations involved with these agent classes make discussions with patients of treatment decisions crucial.
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.